Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Research & Development of $22.13 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), down 18.7% from $27.21 million a year earlier but up 13.8% from the prior quarter.
Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at Enanta Pharmaceuticals was $86.24 million, down 24.2% year-over-year; for FY2025 (ended Sep 30, 2025), it was $106.74 million, down 18.8% from FY2024.
- Annual Research & Development has declined for four consecutive fiscal years, with a five-year compound annual growth rate of -4.8% (FY2020 to FY2025).
- In prior fiscal years, Enanta Pharmaceuticals' Research & Development was $131.48 million in FY2024 (-19.6%), $163.52 million in FY2023 (-0.6%), $164.52 million in FY2022 (-5.5%) and $174.11 million in FY2021 (+27.3%).
- Quarterly Research & Development has run from a low of $19.44 million in fiscal Q2 2026 to a high of $48.95 million in fiscal Q4 2021 over five years.
- On a year-over-year basis, Research & Development has declined in each of the last 11 quarters, with an average decline of 20.2% over the last eight quarters.
- The strongest year-over-year quarter for Research & Development in the past five years was fiscal Q4 2021, with growth of 33.4%; the weakest was fiscal Q3 2024, with a decline of 33.1%.
- According to Business Quant data, Research & Development for the three prior fiscal quarters was $19.44 million (Q2 2026), $20.86 million (Q1 2026) and $23.81 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Enanta Pharmaceuticals | 367.20 Mn | -360.79 Mn | - | 22.13 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.13 Mn |
| Mar 31, 2026 | 19.44 Mn |
| Dec 31, 2025 | 20.86 Mn |
| Sep 30, 2025 | 23.81 Mn |
| Jun 30, 2025 | 27.21 Mn |
| Mar 31, 2025 | 28.07 Mn |
| Dec 31, 2024 | 27.66 Mn |
| Sep 30, 2024 | 30.78 Mn |
| Jun 30, 2024 | 28.74 Mn |
| Mar 31, 2024 | 35.59 Mn |
| Dec 31, 2023 | 36.37 Mn |
| Sep 30, 2023 | 36.17 Mn |
| Jun 30, 2023 | 42.99 Mn |
| Mar 31, 2023 | 43.47 Mn |
| Dec 31, 2022 | 40.90 Mn |
| Sep 30, 2022 | 34.80 Mn |
| Jun 30, 2022 | 39.09 Mn |
| Mar 31, 2022 | 42.09 Mn |
| Dec 31, 2021 | 48.55 Mn |
| Sep 30, 2021 | 48.95 Mn |
Enanta Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ENTA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ENTA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ENTA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();